Rituximab selectively suppresses specific islet antibodies

Diabetes

Volumn 60, Issue 10, 2011, Pages 2560-2565

  Yu, Liping ^a   Herold, Kevan ^b   Krause Steinrauf, Heidi ^c   McGee, Paula L ^c   Bundy, Brian ^d   Pugliese, Alberto ^e   Krischer, Jeff ^f   Eisenbarth, George S ^a  

^a UNIVERSITY OF COLORADO DENVER   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c GEORGE WASHINGTON UNIVERSITY   (United States)

^d ROSWELL PARK CANCER INSTITUTE   (United States)

^e UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; C PEPTIDE; GLUTAMATE DECARBOXYLASE 65 ANTIBODY; INSULIN; INSULIN ANTIBODY; INSULINOMA ASSOCIATED PROTEIN 2 ANTIBODY; PANCREAS ISLET CELL ANTIBODY; PLACEBO; PROTEIN ANTIBODY; RITUXIMAB; UNCLASSIFIED DRUG; ZINC TRANSPORTER 8 ANTIBODY;

ADOLESCENT; ADULT; ARTICLE; CHILD; CONTROLLED STUDY; DRUG EFFECT; FOLLOW UP; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RADIOIMMUNOASSAY; SCHOOL CHILD; SINGLE BLIND PROCEDURE; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; AUTOANTIBODIES; CATION TRANSPORT PROTEINS; CHILD; DIABETES MELLITUS, TYPE 1; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; GLUTAMATE DECARBOXYLASE; HUMANS; IMMUNOLOGIC FACTORS; INSULIN; ISLETS OF LANGERHANS; RECEPTOR-LIKE PROTEIN TYROSINE PHOSPHATASES, CLASS 8; YOUNG ADULT;

EID: 80053434203     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db11-0674     Document Type: Article

References (33)

1. Maloney DG, Liles TM, Czerwinski DK, et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 1994;84:2457-2466 (Pubitemid 24317376)
2. Hauser SL, Waubant E, Arnold DL, et al.; HERMES Trial Group. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008;358:676-688 (Pubitemid 351240747)
3. El Fassi D, Nielsen CH, Bonnema SJ, Hasselbalch HC, Hegedüs L. B lymphocyte depletion with the monoclonal antibody rituximab in Graves' disease: a controlled pilot study. J Clin Endocrinol Metab 2007;92:1769-1772 (Pubitemid 46997186)
4. El Fassi D, Banga JP, Gilbert JA, Padoa C, Hegedüs L, Nielsen CH. Treatment of Graves' disease with rituximab specifically reduces the production of thyroid stimulating autoantibodies. Clin Immunol 2009;130:252-258
5. Huang H, Benoist C, Mathis D. Rituximab specifically depletes short-lived autoreactive plasma cells in a mouse model of inflammatory arthritis. Proc Natl Acad Sci USA 2010;107:4658-4663
6. Bluestone JA, Herold K, Eisenbarth G. Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature 2010;464:1293-1300
7. Martin S, Wolf-Eichbaum D, Duinkerken G, et al. Development of type 1 diabetes despite severe hereditary B-lymphocyte deficiency. N Engl J Med 2001;345:1036-1040
8. Greeley SA, Katsumata M, Yu L, et al. Elimination of maternally transmitted autoantibodies prevents diabetes in nonobese diabetic mice. Nat Med 2002;8:399-402 (Pubitemid 34407036)
9. Zekavat G, Rostami SY, Badkerhanian A, et al. In vivo BLyS/BAFF neutralization ameliorates islet-directed autoimmunity in nonobese diabetic mice. J Immunol 2008;181:8133-8144
10. Silveira PA, Johnson E, Chapman HD, Bui T, Tisch RM, Serreze DV. The preferential ability of B lymphocytes to act as diabetogenic APC in NOD mice depends on expression of self-antigen-specific immunoglobulin receptors. Eur J Immunol 2002;32:3657-3666 (Pubitemid 36024402)
11. Hu C, Deng S, Wong FS, Wen L. Anti-CD20 treatment prolongs syngeneic islet graft survival and delays the onset of recurrent autoimmune diabetes. Ann N Y Acad Sci 2008;1150:217-219
12. Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, et al.; Type 1 Diabetes TrialNet Anti-CD20 Study Group. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med 2009;361:2143-2152
13. Yu L, Rewers M, Gianani R, et al. Antiislet autoantibodies usually develop sequentially rather than simultaneously. J Clin Endocrinol Metab 1996;81:4264-4267 (Pubitemid 26412027)
14. Yu L, Robles DT, Abiru N, et al. Early expression of antiinsulin autoantibodies of humans and the NOD mouse: evidence for early determination of subsequent diabetes. Proc Natl Acad Sci USA 2000;97:1701-1706 (Pubitemid 30118506)
15. Bingley PJ. Clinical applications of diabetes antibody testing. J Clin Endocrinol Metab 2010;95:25-33
16. Bottazzo GF, Florin-Christensen A, Doniach D. Islet-cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies. Lancet 1974;2:1279-1283
17. Palmer JP, Asplin CM, Clemons P, et al. Insulin antibodies in insulin-dependent diabetics before insulin treatment. Science 1983;222:1337-1339 (Pubitemid 14204704)
18. Achenbach P, Koczwara K, Knopff A, Naserke H, Ziegler AG, Bonifacio E. Mature high-affinity immune responses to (pro)insulin anticipate the autoimmune cascade that leads to type 1 diabetes. J Clin Invest 2004;114:589-597 (Pubitemid 39572109)
19. Vardi P, Ziegler AG, Mathews JH, et al. Concentration of insulin autoantibodies at onset of type I diabetes: inverse log-linear correlation with age. Diabetes Care 1988;11:736-739
20. Arslanian SA, Becker DJ, Rabin B, et al. Correlates of insulin antibodies in newly diagnosed children with insulin-dependent diabetes before insulin therapy. Diabetes 1985;34:926-930 (Pubitemid 15016558)
21. Wenzlau JM, Walter M, Gardner TJ, et al. Kinetics of the post-onset decline in zinc transporter 8 autoantibodies in type 1 diabetic human subjects. J Clin Endocrinol Metab 2010;95:4712-4719
22. Achenbach P, Bonifacio E, Williams AJ, Ziegler AG, Gale EA, Bingley PJ; ENDIT Group. Autoantibodies to IA-2beta improve diabetes risk assessment in high-risk relatives. Diabetologia 2008;51:488-492
23. van der Kolk LE, Baars JW, Prins MH, van Oers MH. Rituximab treatment results in impaired secondary humoral immune responsiveness. Blood 2002;100:2257-2259 (Pubitemid 35001266)
24. Gonzalez-Stawinski GV, Yu PB, Love SD, Parker W, Davis RD Jr. Hapten-induced primary and memory humoral responses are inhibited by the infusion of anti-CD20 monoclonal antibody (IDEC-C2B8, Rituximab). Clin Immunol 2001;98:175-179
25. Wang J, Miao D, Babu S, et al. Prevalence of autoantibody-negative diabetes is not rare at all ages and increases with older age and obesity. J Clin Endocrinol Metab 2007;92:88-92 (Pubitemid 46075008)
26. Krishnamurthy B, Dudek NL, McKenzie MD, et al. Responses against islet antigens in NOD mice are prevented by tolerance to proinsulin but not IGRP. J Clin Invest 2006;116:3258-3265 (Pubitemid 44878640)
27. Nakayama M, Abiru N, Moriyama H, et al. Prime role for an insulin epitope in the development of type 1 diabetes in NOD mice. Nature 2005;435:220-223 (Pubitemid 40685949)
28. Yamamoto T, Yamato E, Tashiro F, et al. Development of autoimmune diabetes in glutamic acid decarboxylase 65 (GAD65) knockout NOD mice. Diabetologia 2004;47:221-224 (Pubitemid 38315358)
29. Kubosaki A, Miura J, Notkins AL. IA-2 is not required for the development of diabetes in NOD mice. Diabetologia 2004;47:149-150 (Pubitemid 38141956)
30. Bell GI, Horita S, Karam JH. A polymorphic locus near the human insulin gene is associated with insulin-dependent diabetesmellitus. Diabetes 1984;33:176-183 (Pubitemid 14184705)
31. Pugliese A, Zeller M, Fernandez A Jr, et al. The insulin gene is transcribed in the human thymus and transcription levels correlated with allelic variation at the INS VNTR-IDDM2 susceptibility locus for type 1 diabetes. Nat Genet 1997;15:293-297 (Pubitemid 27098726)
32. Vafiadis P, Bennett ST, Todd JA, et al. Insulin expression in human thymus is modulated by INS VNTR alleles at the IDDM2 locus. Nat Genet 1997;15:289-292 (Pubitemid 27098725)
33. Steck AJ, Johnson K, Barriga K, et al. Age of islet autoantibody appearance and mean levels of insulin, but not GAD or IA-2 autoantibodies, predict age of diagnosis of type 1 diabetes: Diabetes Autoimmunity Study in the Young. Diabetes Care 2011;34:1397-1399